All Posts Tagged With: "NKTR"
(AIB) Company News for May 18, 2011 – Corporate Summary
• Dell Inc. (NASDAQ:DELL) reported Q1 EPS of $0.55, higher than the Zacks Consensus Estimate of $0.43 per share. Revenue for the quarter edged up 1% year-over-year to $15.02 billion, falling short of the Zacks Consensus...
(ABT) Company News for January 20, 2011 – Corporate Summary
• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night
• Adtran Inc (NASDAQ:ADTN) increased...
(SIGA) These Healthcare Stocks Are Ready to Move Next Week
by Marc Lichtenfeld, Investment U’s Senior Analyst
Wednesday,...
(NKTR) Nektar Therapeutics Announces Preliminary Data
Recently, Nektar Therapeutics (NKTR) announced preliminary results from the first stage of phase II study of its experimental ovarian cancer drug, NKTR-102. It has been observed that the drug, tested in women...
(NKTR) Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year
by Marc Lichtenfeld, Healthcare Expert
Wednesday, January 6, 2010: Issue...
(AZN) AstraZeneca Beats Expectations and Raises
AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased...
(NKTR) The F.I.R.S.T. System: Searching For the “Holy Grail” of Investing
by Marc Lichtenfeld, Healthcare Expert
Wednesday, October 28, 2009: Issue...
(NKTR) Nektar Therapeutics Presents Favorable Phase II Trial Data
Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management’s 20th Annual Clinical Meeting in...
(AZN) AstraZeneca and Nektar Therapeutics Deal to Add Value
Recently, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation,...
(AZN) AstraZeneca Signs Licensing Deal With Nektar Therapeutics
Yesterday, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced constipation,...